Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • M&A
  • News
  • Penny Stocks

Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio

By Vandana Singh
November 8, 1:26 PM
Avenue Therapeutics Inc (NASDAQ:ATXI) acquired Baergic Bio Inc pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech Inc (NASDAQ:FBIO).…

ATXI

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

“Rafael Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 17/261,237 Titled ‘Therapeutic Methods And Compositions For Treating Pancreatic Cancer Using 6,8-BIS-BENZYLTHIO-OCTANOIC ACID'” – USPTO

By Benzinga Newsdesk
November 8, 12:39 PM
https://patentcenter.uspto.gov/#!/applications/17261237/ifw/docs

RFL

Read More
1 minute read
  • FDA
  • News

Ionis Highlights Data From GSK’s Phase 2b Clinical Study Of Bepirovirsen

By Benzinga Newsdesk
November 8, 12:06 PM
onis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense

IONS

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

“Inseego Granted U.S. Patent #11490812 For ‘Systems And Methods For Monitoring And Detecting Symptoms Of Infectious Conditions’. Mentions HIV And Covid. Bounce Chart. Search 11490812” – USPTO

By Benzinga Newsdesk
November 8, 11:47 AM
Patent Public Search | USPTO    

INSG

Read More
5 minute read
  • Biotech
  • Events
  • FDA
  • General
  • News

Sustained Patient Response To KRYSTEXXA Injection With Methotrexate Compared To KRYSTEXXA Alone Shown Through Month 12 In MIRROR Randomized Controlled Trial

By Benzinga Newsdesk
November 8, 11:01 AM
-- Month 12 results from MIRROR randomized controlled trial to be featured on Nov. 13, 11:45 a.m. EST during plenary session at the American College of Rheumatology Convergence 2022 -- -- Imaging analyses visualize

HZNP

Read More
1 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Movers
  • News
  • Trading Ideas

Perrigo Shares Fall As Investors React To Lowered FY22 Profit Guidance

By Vandana Singh
November 8, 10:52 AM
Perrigo Company plc’s (NYSE: PRGO) Q3 FY22 sales increased 5.5% Y/Y or 12.3%, excluding the impact of currency translation to $1.10 billion,…

PRGO

Read More
4 minute read
  • Biotech
  • FDA
  • General
  • News

Bicycle Therapeutics Announces First Patient Dosed In BT8009 Phase II Expansion Cohorts And Provides Program Update

By Benzinga Newsdesk
November 8, 8:05 AM
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updates from

BCYC

Read More
3 minute read
  • Biotech
  • Events
  • FDA
  • General
  • News

Reported Late Monday, Intercept Announces Development Program For Next-Generation FXR Agonist INT-787 In Severe Alcohol-Associated Hepatitis

By Benzinga Newsdesk
November 8, 1:18 AM
First-in-human data shared at The Liver Meeting® 2022 supported a favorable safety and tolerability profile for INT-787 in healthy adults   Company announces severe alcohol-associated hepatitis (sAH), a

ICPT

Read More
2 minute read
  • Biotech
  • General
  • News

Reported Late Monday, Allarity Therapeutics Announces Adjournment Of 2022 Annual Meeting of Stockholders Until December 2, 2022

By Benzinga Newsdesk
November 8, 1:16 AM
Cambridge, MA U.S.A. (November 7, 2022) — Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with

ALLR

Read More
2 minute read
  • Biotech
  • Events
  • FDA
  • General
  • News

Werewolf Therapeutics To Present Preclinical Data At Society For Immunotherapy Of Cancer Annual Meeting And Participate In Upcoming Investor Conferences

By Benzinga Newsdesk
November 7, 5:59 PM
Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to

HOWL

Posts pagination

Previous 1 … 635 636 637 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service